All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Depression Screening

September 30th 2013

Two question survey works as well as longer surveys.

FDA Approves Neoadjuvant Pertuzumab Regimen

September 30th 2013

Pertuzumab in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer

The Cancer Therapy & Research Center at the University of Texas Health Science Center Joins OncLive's Strategic Alliance Partnership

September 25th 2013

World-class cancer research and treatment center is the latest to partner with OncLive to promote its research, events, and initiatives

Distress Assessment

September 25th 2013

Researchers find that patients are not referred for supportive care services.

Questions Remain Regarding Prognostic Value of BRAF Mutation in Papillary Thyroid Cancer

September 24th 2013

Several recently published papers have introduced contradicting findings on the usefulness of BRAF status for predicting the presence of aggressive papillary thyroid cancer.

Cancer Care is in Crisis Mode

September 18th 2013

The IOM makes 10 recommendations for improving care.

Learn More About Robotic Thoracic Surgery Offered at UC Davis

September 18th 2013

The section of General Thoracic Surgery at UC Davis is offering Robotic Thoracic Surgery to further enhance our top regional minimally invasive thoracic surgery program.

Volasertib Given Breakthrough Therapy Designation for AML

September 17th 2013

The novel PLK1 inhibitor volasertib in combination with low-dose cytarabine has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with untreated AML.

First Generic Version of Capecitabine Gains FDA Approval

September 16th 2013

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

Dabrafenib and Trametinib Combination Granted Priority Review Designation by FDA

September 16th 2013

The FDA has granted Priority Review designation to dabrafenib (Tafinlar) and trametinib (Mekinist) as a combination treatment for patients with unresectable or metastatic melanoma with a BRAFV600E/K mutation.

Ofatumumab Receives Breakthrough Therapy Designation for Earlier Use in CLL

September 16th 2013

The monoclonal antibody ofatumumab has received Breakthrough Therapy designation from the FDA that could allow for earlier use in patients with chronic lymphocytic leukemia.

In Historic Vote, ODAC Suggests Approval of Neoadjuvant Pertuzumab Regimen

September 12th 2013

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

Toxicity Clinics

September 12th 2013

Found to be helpful for patients with head and neck cancer.

Ipilimumab Fails to Prolong Survival in mCRPC

September 12th 2013

A phase III trial examining the anti-CTLA-4 immune checkpoint inhibitor ipilimumab in men with metastatic castration-resistant prostate cancer failed to meet its primary endpoint of prolongation in overall survival.

Breakthrough Designation Granted to Entinostat for Advanced Breast Cancer

September 11th 2013

The novel HDAC inhibitor entinostat in combination with exemestane has received a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced ER-positive breast cancer.

FDA Panel Set to Vote on Milestone Neoadjuvant Pertuzumab Combo

September 11th 2013

The hope for many targeted therapies is that they will eventually be used in patients with earlier stage disease; for the breast cancer drug pertuzumab (Perjeta), that hope is being put to the test.

FDA Approves Nab-Paclitaxel for Advanced Pancreatic Cancer

September 6th 2013

The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.

Investigational Vaccine Fails to Extend Disease-Free Survival in Certain Patients with Advanced Melanoma

September 5th 2013

The investigational MAGE-A3 immunotherapeutic did not significantly extend disease-free survival (DFS) in certain patients with postsurgical melanoma when compared with a placebo in a phase III study.

Maintenance Olaparib Resurrected for Phase III Program

September 4th 2013

The first patient has been enrolled in a phase III clinical program investigating treatment with olaparib for patients with BRCA-mutated ovarian cancer, marking another step in the revived development of an agent once relegated to the sidelines.

Comprehensive Lung Cancer Screening at UC Davis

August 28th 2013

UC Davis CLSP is a multidisciplinary program for comprehensive lung cancer screening.